Details
Stereochemistry | ACHIRAL |
Molecular Formula | C15H14O4 |
Molecular Weight | 258.2693 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(\C=C\C2=CC(OC)=CC(=O)O2)C=C1
InChI
InChIKey=XLHIYUYCSMZCCC-VMPITWQZSA-N
InChI=1S/C15H14O4/c1-17-12-6-3-11(4-7-12)5-8-13-9-14(18-2)10-15(16)19-13/h3-10H,1-2H3/b8-5+
Molecular Formula | C15H14O4 |
Molecular Weight | 258.2693 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 1 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/20734326Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28959001 | https://www.ncbi.nlm.nih.gov/pubmed/22525682 | https://www.ncbi.nlm.nih.gov/pubmed/22510965 | https://www.ncbi.nlm.nih.gov/pubmed/17059882
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20734326
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/28959001 | https://www.ncbi.nlm.nih.gov/pubmed/22525682 | https://www.ncbi.nlm.nih.gov/pubmed/22510965 | https://www.ncbi.nlm.nih.gov/pubmed/17059882
Yangonin is a natural kavalactone found in the kava plant. Yangonin has been shown to possess binding affinity for the cannabinoid receptor CB1, where it behaves as an agonist. Yangonin also inhibits anchorage-dependent and independent growth of bladder cancer cell lines through induction of autophagic cell death. Yangonin displays marked in vitro toxicity on human hepatocytes with approximately 40% reduction in viability based on an ethidium bromide assay and FDA advises against the use of kava in food due to the potential risk of severe liver damage.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL218 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22525682 |
0.72 µM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17059882
Groups of 10 male and 10 female rats were administered kava extract (Yangonin: 42.76%) by gavage at 0, 0.125, 0.25, 0.5, 1.0, and 2.0 g/kg/day for 90 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28959001
RT4, T24, UMUC3, HT1376, and HT 1197 cells, as well as TSC1+/+/p53+/+, TSC1–/–/p53+/+, TSC2+/+/ p53–/–, TSC2–/–/p53–/– MEFs, LKB knockout and wildtype MEFs were plated at a density of 2 x 10^5 per well in 24-well culture plates in medium containing 10% FBS. After 24 hours, the medium was refreshed and then was either left untreated or was treated with yangonin (1.25-100mg/ml), docetaxel or flavokawain A After treatment, MTT was added to the wells at a final concentration of 1 mg/mL and incubated at 37°C for 3 hours. The absorbance was determined at 570 nm. Cell sensitivity to drug treatment was expressed as the drug concentration that yielded 50% cell growth inhibition
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 19:48:26 GMT 2023
by
admin
on
Fri Dec 15 19:48:26 GMT 2023
|
Record UNII |
R970U49V3C
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DSLD |
2592 (Number of products:13)
Created by
admin on Fri Dec 15 19:48:26 GMT 2023 , Edited by admin on Fri Dec 15 19:48:26 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C110481
Created by
admin on Fri Dec 15 19:48:26 GMT 2023 , Edited by admin on Fri Dec 15 19:48:26 GMT 2023
|
PRIMARY | |||
|
R970U49V3C
Created by
admin on Fri Dec 15 19:48:26 GMT 2023 , Edited by admin on Fri Dec 15 19:48:26 GMT 2023
|
PRIMARY | |||
|
500-62-9
Created by
admin on Fri Dec 15 19:48:26 GMT 2023 , Edited by admin on Fri Dec 15 19:48:26 GMT 2023
|
PRIMARY | |||
|
m11561
Created by
admin on Fri Dec 15 19:48:26 GMT 2023 , Edited by admin on Fri Dec 15 19:48:26 GMT 2023
|
PRIMARY | Merck Index | ||
|
212502
Created by
admin on Fri Dec 15 19:48:26 GMT 2023 , Edited by admin on Fri Dec 15 19:48:26 GMT 2023
|
PRIMARY | |||
|
5281575
Created by
admin on Fri Dec 15 19:48:26 GMT 2023 , Edited by admin on Fri Dec 15 19:48:26 GMT 2023
|
PRIMARY | |||
|
DTXSID4034102
Created by
admin on Fri Dec 15 19:48:26 GMT 2023 , Edited by admin on Fri Dec 15 19:48:26 GMT 2023
|
PRIMARY | |||
|
YANGONIN
Created by
admin on Fri Dec 15 19:48:26 GMT 2023 , Edited by admin on Fri Dec 15 19:48:26 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> CONSTITUENT ALWAYS PRESENT |